Driehaus Capital Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Driehaus Capital Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-37,411	Closed	-$2.31M	–	728
2014 Q2	$2.31M	Sell	37,411 -1,017	-3%	-$59.1K	0.08%	316
2014 Q1	$2.5M	Buy	+38,428	New	+$2.6M	0.08%	301
2013 Q4	–	Sell	-42,251	Closed	-$2.59M	–	602
2013 Q3	$2.59M	Buy	42,251 +9,037	+27%	+$612K	0.1%	241
2013 Q2	$1.94M	Buy	+33,214	New	+$2.04M	0.08%	268

Other funds holding OREX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Driehaus Capital Management's OREX Position: Q3 2014 in Review

Driehaus Capital Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2014, closing a stake of 37,411 shares — an estimated $2.31M sold.

Driehaus Capital Management first reported a position in OREX in Q2 2013 and held it in 4 quarters. The position peaked at $2.59M in Q3 2013. 128 funds tracked by Wall St. Rank hold OREX as of Q3 2014.

Driehaus Capital Management reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
Driehaus Capital Management sold 37,411 Orexigen Therapeutics, Inc. shares in Q3 2014, an estimated $2.31M.
Driehaus Capital Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 4 quarters.
Driehaus Capital Management's Orexigen Therapeutics, Inc. position peaked at $2.59M in Q3 2013.
128 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2014.

Based on Driehaus Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.